suggesting that filtration is the only method of leukocyte reduction. However, the vehicle of CMV transmission by transfusion is accepted as the leukocyte, as supported by clinical and laboratory studies.'.' Therefore, the objective for obtaining seronegative equivalent blood products is effective and consistent removal of leukocytes without regard to the method of removal. In studies referenced by Bowden et al,' centrifugation was effectively used by other groups to reduce the total white blood cell (WBC) burden per transfusion for the prevention of primary CMV infection. de Graan-Hentzen et a14 performed an extra centrifugation step to remove WBCs from platelet concentrates, resulting in less than 1 X IO' total WBCs per 4 to 6 units. Bowden et al' performed a final centrifugation on a pool of 4 to 6 platelet units to achieve greater than 99.8% leukocyte removal. It is also generally accepted that frozedthawed, deglycerolized red blood cells do not transmit CMV and are equivalent to seronegative products.' New technology for WBC removal has recently been reported by Elfath et al' that is capable of reliably providing greater than 99% of apheresis platelets with less than l X IO6 total WBCs without the need for secondary filtration. Therefore, other viable alternatives to effective, reliable leukocyte reduction exist, and others may be on the development horizon. Although filtration remains a suitable approach, any means of consistent leukocyte reduction should yield a product effective in prevention of CMV infection. We are interested in Bowden et al's views on this issue. 
Response
The letter by Dumont and Schuyler raises a very good point, namely that filtration is not the only method of leukocyte depletion that can result in reduction of the risk of CMV. Certainly, the use of frozen deglycerolyzed red blood cells was the first reported method shown to result in a CMV-safe product. The most common question asked of the authors of our report is whether current pheresis machines, which result in a log reduction of leukocytes to less than IO'/transfusion, should also be able to provide CMV-safe blood without further filtration. Although this technology has not been evaluated in studies with CMV endpoints, the answer is likely to be yes, as long as a 3 log or greater leukocyte reduction is achieved.
That appears to be the critical factor. We appreciate the clarification of this issue. 
